Drugs / Tovinontrine
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02998450 | Oct 2016 → Jul 2017 | sickle cell-beta zero-thalassemia, sickle cell-hemoglobin c disease syndrome | Cardurion Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 27 trials | ||||||
| Phase 2 | NCT06215586 | Feb 2024 → Sep 2025 | heart failure | Cardurion Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT06215911 | Feb 2024 → Oct 2025 | heart failure | Cardurion Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT05312021 | Apr 2022 → Sep 2023 | diastolic heart failure | Cardurion Pharmaceuticals, Inc. | Withdrawn | No outcome recorded |
| Phase 2 | NCT04411082 | Oct 2020 → Mar 2022 | beta thalassemia | Cardurion Pharmaceuticals, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT04474314 | Aug 2020 → Mar 2022 | sickle cell disease | Cardurion Pharmaceuticals, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT04053803 | May 2019 → Mar 2025 overdue | sickle cell disease | Imara, Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03401112 | Jan 2018 → Aug 2020 | sickle cell disease | Cardurion Pharmaceuticals, Inc. | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-08-27 | Cardurion Pharmaceuticals, Inc. | Cardurion Pharmaceuticals Announces Late-Breaking Presentation of Phase 2 Results for Tovinontrine (CRD-750), a PDE9 Inhibitor, in Heart Failure cardurion.com ↗ |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tovinontrine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06215911 ↗ |
| Known as | 68722 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297290 ↗ |
| Known as | AF-68722 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297290 ↗ |
| Known as | CK-1598 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297290 ↗ |
| Known as | CRD-750 | “Tovinontrine (CRD-750)” NCT06215911 ↗1“Tovinontrine (CRD-750” NCT06215586 ↗ |
| Known as | IMR-687 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04411082 ↗ |
| Known as | TOVINONTRINA | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297290 ↗ |
| Action | Inhibit | “IMR-687 (phosphodiesterase (PDE) 9 inhibitor)” NCT04411082 ↗1“Phosphodiesterase 9A inhibitor” CHEMBL4297290 ↗ |
| Modality | Small molecule | — CHEMBL4297290 ↗ |
| Route | Oral | “administered orally following an overnight fast” NCT02998450 ↗ |
| Target | PDE9A | “Phosphodiesterase 9A inhibitor” CHEMBL4297290 ↗ |